Retatrutide purity was outstanding
Running metabolic assays with Retatrutide. Lot had >99% purity by reverse-phase HPLC — above spec. Mass spec confirmed molecular weight. Best peptide supplier we've worked with.
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally via MC3R/MC4R, distinct from PDE5 inhibitor mechanisms.
| Format | Lyophilized Vial |
|---|---|
| Dosage | 10mg |
| Purity | >98% |
| Sub-Line | APEX |
In Stock — Overnight and 2–3 day delivery available
PT-141 (Bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH and the first melanocortin-based compound to receive FDA approval for sexual dysfunction. Approved as Vyleesi in June 2019 for HSDD in premenopausal women, it provides a uniquely strong clinical evidence base for research use.
PT-141 is studied in male and female sexual dysfunction, melanocortin neurocircuitry, obesity (MC4R), and inflammatory pain. Phase III RECONNECT trial (n=1,267) demonstrated significant HSDD improvement vs placebo.
For Research Use Only. Rainbow Peptide supplies PT-141 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Third-Party Verified
We don't just claim purity — we prove it. Every batch of PT-141 is independently tested by an accredited third-party laboratory before it reaches you. Your COA is linked to your specific lot number.
Verified purchases from active research labs and scientists
Running metabolic assays with Retatrutide. Lot had >99% purity by reverse-phase HPLC — above spec. Mass spec confirmed molecular weight. Best peptide supplier we've worked with.
Internal verification confirmed COA data. Purity was 98.6% HPLC. Peptide behavior in our assay was consistent with published data. Will order again for next study phase.
AOD-9604 arrived quickly and in excellent condition. Cold pack preserved temperature. COA was thorough. Results in metabolic assays consistent with expected parameters.